Compare Cytokinetics Inc (CYTK) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Nuscale Power Corporation — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Nuscale Power Corporation trades at $7.2 (market cap $3.00B). The key difference: Cytokinetics Inc is far larger — about 2.9× Nuscale Power Corporation's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Nuscale Power Corporation for 29 Days on average.
| CYTK | SMR | |
|---|---|---|
Market Cap | $8.62B | $3.00B |
Volume | 2,594,626 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $87.26 | $53.43 |
52-Week Low | $54.76 | $7.32 |
Typical Hold Time | 19 Days | 29 Days |
Enterprise Value | $8.72B | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
NuScale Power (SMR) trades at $7.32, down 4.56% today, amid bearish technical signals and challenging fundamentals. The company reported significant losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Despite analyst consensus pointing to a $11.25 price target with 50% buy ratings, recent news highlights investor concerns including an ongoing legal investigation announced by Pomerantz Law Firm on October 1, 2026.
The stock faces substantial execution risks as it burns cash to commercialize small modular reactor technology. While nuclear energy presents long-term growth potential, SMR's path to profitability remains uncertain given current financial metrics and competitive pressures from established players like GE Vernova. The wide analyst target range ($6-$16) reflects divided sentiment on the company's prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
